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survival of hepatocellular carcinoma
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Background: Growing evidences indicate microRNAs play important roles in cancer development, progression,
metastasis and may constitute robust biomarkers for cancer prognosis. The aim of this study was to identify the
clinical and functional association of microRNA-20a (miR-20a) in hepatocellular carcinoma (HCC).
Methods: MiR-20a was detected using Taqman real-time polymerase chain reaction. Kaplan-Meier and Cox
proportional regression analyses were utilized to determine the association of miR-20a with survival of patients.
The potential functions of miR-20a on proliferation were evaluated by proliferation and flow cytometry analysis.
The direct target gene of miR-20a was also identified by luciferase reporter assays.
Results: MiR-20a was lower in primary HCC than normal liver, and were further decreased in those with post-liver
transplantation (LT) HCC recurrence compared with those with non-recurrence (p = 0.001). Patients with lower
miR-20a expression had significantly poorer recurrence-free survival (RFS, Log rank p < 0.001) and overall survival
(OS, Log rank p < 0.001). Multivariate analysis revealed that lower miR-20a was an independent predictor of poor
prognosis. MiR-20a restoration could suppress HepG2 and SMMC-7721 cells proliferation and induce cell cycle G1
arrest and apoptosis. Subsequent investigations revealed that miR-20a directly targeted myeloid cell leukemia
sequence 1 (Mcl-1) and reduced the endogenous protein level of Mcl-1 in HCC cells.
Conclusions: MiR-20a is decreased in HCCs and correlates with HCC recurrence and prognosis. Down-regulation of
miR-20a increases the proliferation abilities of HCC cells. Our findings suggest miR-20a may represent a novel
potential therapeutic target and biomarker for survival of HCC patients.
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Hepatocellular carcinoma (HCC) is the third leading cause
of cancer-related deaths in the world, with an estimated 21
000 new cases diagnosed and accounting for ~700 000
deaths annually [1]. To date, surgery remains the best
prognostic tool for long-term survival of HCC patients;
however, more than 80% of patients with HCC have under-
lying cirrhosis, and of these patients, only 10% to 15% are
potentially resectable [2]. The rest are unresectable because
of size, location, or severity of underlying liver disease.
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reproduction in any medium, provided the oroption for these HCC patients, especially in cirrhotic
patients without local or distant metastasis of HCC [3].
However, the risk of HCC recurrence is remain the major
concern in patients transplanted for HCC. Understanding
the molecular alteration that distinguish progressive from
nonprogressive HCC will allow the identification of novel
prognositic markers or therapeutic targets and may be
useful to guide the post-LT surveillance. Recently, increas-
ing evidences indicate that microRNAs can be potential
tools for cancer diagnosis and prognosis [4]. MicroRNAs
are small noncoding RNA gene products about 22 nt long
that are found in divers organisms and play key roles
in post-transcriptional regulation of targeted gene
expression through sequence-specific interaction with the
30-untranslated region (30-UTR) of targeted genes [5].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics of the 100 HCC patients
according to high- or low miR-20a expression level
Parameter N Patients with
low miR-20a
expression
Patients with
high miR-20a
expression
P-value
Age 100 57.820 ± 7.330 53.64 ± 8.341 0.212†
Sex
Male 84 44 40 0.585‡
Female 16 6 10
Underlying liver
disease
HBV 95 47 48 1.000§
others 5 3 2
Cirrhosis
Yes 95 47 48 1.000 §
No 5 3 2
Tumor stage
I + II 66 32 34 0.673‡
III 34 18 16
Histologic grade
Differentiated 88 41 47 0.065§
Undifferentiated 12 9 3
Milan criteria
In 55 24 31 0.159‡
Out 45 26 19
Tumor size (cm)
≤5 60 24 36 0.014‡
>5 40 26 14
Multinodular
Yes 43 25 18 0.034 ‡
No 57 25 32
Micro-vascular
invasion
Yes 22 16 6 0.016 ‡
No 78 34 44
pre-LT serum
AFP level
≤400 (ng/ml) 63 30 33 0.534 ‡
>400 (ng/ml) 37 20 17
Overall survival 42/100 11/50 31/50 -
HCC recurrence 58/100 37/50 21/50 -
NOTE: AFP, alpha-fetoprotein. †Unpaired student t test; ‡chi-square test;
§Fisher’s exact test.
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tions such as, embryonic development, cell growth, apop-
tosis, and differentiation. However, dysregulation of
microRNA is also common in various cancers. The
dysregulated miRNAs play roles in carcinogenesis or
tumor progression by altering the normal gene expression
patterns.
MicroRNA-20a (miR-20a) was found to be down-
regulated in several solid tumors, such as breast cancer [6]
and pancreatic carcinoma [7], while miR-20a were found to
be significantly up-regulated in colon adenocarcinoma [8]
and gliomas [9]. This indicates that miR-20a may be a tis-
sue specific microRNA. On the other hand, miR-20a has
been shown to inhibit proliferation and metastasis of pan-
creatic carcinoma cell by directly down-regulating Stat3,
that is activated in primary pancreatic cancer and is
involved in various physiologic functions, including apop-
tosis, cell cycle regulation, angiogenesis, and metastasis [7].
Bioinformatic target gene predictions followed by experi-
mental target gene validations revealed that miR-20a act in
a common manner by down-regulating an overlapping set
of target genes, including E2F family, cyclin-dependent kin-
ase inhibitor CDKN1a/p21, which were mostly involved in
regulation and execution of G1/S transition in the cell cycle
[10]. Our previous study has shown that miR-20a was
correlated with HCC recurrence [11]. However, the bio-
logical functions of miR-20a in HCC were not clear and the
association between miR-20a and HCC prognosis following
LT has not been evaluated yet.
In our current study, we evaluated miR-20a expression
levels in 100 formalin-fixed paraffin-embedded (FFPE)
tumor tissues of patients with HCC and found that miR-
20a was significantly down-regulated in HCC. Based on
gain-of-function approach, we proved that miR-20a
could inhibit HCC cell proliferation and induce apop-
tosis in vitro. Furthermore, the Mcl-1 (myeloid cell
leukemia sequence 1) protein, an antiapoptotic member
of Bcl-2 family, which is usually overexpressed in a
variety of human cancers including HCC [12] and
plays a pivotal role in protecting cells from apoptosis
and tumor carcinogenesis [13], was identified as a direct
target of miR-20a. This result provided a possible regula-
tion pathway for Mcl-1 and a candidate target for HCC
treatment. We also demonstrated that miR-20a may serve
as a potential therapeutic target and biomarker for
survival of HCC patients following LT.
Materials and methods
Patients and tissue samples
A total of 100 patients undergoing LT for HCC and the
follow-up data about the patients in this study were
obtained from Liver Transplantation Surgery, Shanghai
First People’s Hospital, Shanghai, China, from 2002 to
2007. All the patients were followed until December2010. The median recurrence-free period was 12 months
for patients with HCC recurrence and 64 months for
patients without HCC recurrence. All of these 100 patients
fulfilled the Up-To-Seven transplantation criteria for HCC
[14] and none of them had macro-vascular invasion. HCC
samples were from the FFPE tissue blocks and the normal
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The clinicopathological features of patients were summa-
rized in Table 1. Pre-LT serum AFP level stratification was
according to the previous study [15]. All patients provided
informed consent according to the protocols approved
by the Institutional Review Boards of Shanghai First
People’s Hospital.Cell culture and transfection
All the cell lines used in this study were purchased
from the cell bank of the Chinese Academy of Sciences
and grown in DMEM (GIBCO, Grand Island, NY),
supplemented with 10% fetal bovine serum (Sigma-Aldrich,
St Louis, MO), 2 mM glutamine, 100 U of penicillin/ml
and 100 μg of streptomycin/ml (Cambrex, Verviers,
Belgium). All cells were incubated at 37°C in a humidified
chamber supplemented with 5% CO2. Control negative
oligonucleotide, and double-stranded RNAs that mimic
endogenous precursor miR-20a were purchased from
Ambion (Ambion, Austin, TX) were transfected into cells
using Oligofectamine (Invitrogen, Carlsbad, CA) according
to the manufacturer’s instruction.RNA isolation and Taqman real-time PCR
Total cellular RNA with efficient recovery of small RNA
was isolated from 10 × 15 μm section of FFPE tissues
using RecoverAll™ Total Nucleic Acid Isolation Kit
(Ambion, Forest City, CA) according to the manufac-
turer’s instructions. Taqman real-time polymerase chain
reaction (PCR)-based detection of mature miR-20a was
performed by the TaqMan microRNA assays (Ambion,
Forest City, CA) as described previously [16]. U6 small
RNA was used as an internal control for normalization
and quantification of miR-20a expression. All experiments
were done in triplicate.Cell proliferation assay
Cell proliferation assay was done using cell Titer 96
Aqueous one Solution Cell Proliferation Assay (Promega,
Madison, WI) according to the manufacturer’s protocol.Cell cycle analysis
HepG2 and SMMC-7721 HCC cells were transfected as
described above. After incubated for 48 h, the cells were
typsinized, washed with PBS twice, and then fixed with
cold 75% ethanol at 4°C overnight. The fixed cells were
centrifuged, resuspended in PBS at 1 × 106 cells/ml and
incubated with ribonuclease A and propidium idide
(PI) at 37°C for 30 min, then followed by flow cytometric
analysis using FL2 histogram of a flow cytometer
(FACSort; Becton Dickinson, San Jose, CA).Apoptosis analysis
Cells were harvested at the above indicated time points,
at least 5 × 105 cells were recovered by centrifugation for
evaluation of apoptotic cells with the use of double
staining with annexin V–fluoresein isothiocyanate
(annexin V–FITC) and propidium iodide (PI) (BioVision,
St Pete Beach, FL) according to the manufacturer’s in-
structions, followed by flow cytometric analysis with the
use of the FL-1 and FL-3 channels of a flow cytometer,
where apoptotic cells are defined as annexin V + and PI-.
Luciferase activity assay
For luciferase reporter assay, HEK293T cells were cultured
in 48-well plates and then cotransfected with 10 ng of
either pGL3cm-MCL-1-30UTR-WT or pGL3cm-MCL-1-
30UTR-MUT, 30 pmol of miR-20a precursor or negative
control oligonucleotides, and 2 ng of pRL-TK (Promega,
Madison, WI). Transfection was done using Oligofectamine
(Invitrogen, Carlsbad, CA) according to the manufacturer‘s
protocol. Cells were collected 48 h after transfection and
analyzed using the Dual-Luciferase Reporter Assay
System (Promega, Madison, WI). Experiments were
done independently in triplicate.
Western bolt analysis
Cell lysates were resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, transferred to nitrocel-
lulose membrane (Bio-Rad, Hercules, CA) and blocked in
phosphate-buffered saline/Tween-20 containing 5% nonfat
milk. The membrane was incubared with antibodies for
Mcl-1 (Abcam, Cambridge, MA; 1:1000) or GAPDH
(Sigma, St. Louis, MO; 1:5000). The antigen-antibody
comples was detected using enhanced chemiluminescence
(Pierce, Rockford, IL).
Immunohistochemical (IHC) staining
Paraffin-embedded tissue sections were deparaffinized in
xylene and rehydrated in graded series of ethanols
followed by heat induced epitope retrieval in citrate buffer
(PH 6.0). Mcl-1 expression were detected using a primary
antibody against Mcl-1(Abcam, Cambridge, MA; 1:200).
After incubation with a biotinylaed secondary antibody
and DAB (Dako, Carpenteria, CA), the slides were rinsed
and counterstained with Mayer‘ hematoxylin.
Statistical analysis
Two-sided Student’s t test was used to analyze the differ-
ences in miR-20a expression [17], proliferation, colony for-
mation number, percent of cells in respective cell cycle and
apoptotic rate. Data were presented as mean ± SD from at
least three separate experiments. The Fisher exact test was
used for analysis of categorical data. Association of miR-20a
expression with overall survival (OS) and recurrence-free
survival (RFS) was estimated by Kaplan-Meier method, and
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The multivariate Cox proportional hazard regression ana-
lysis were used to evaluate the contribution of independent
prognostic factors to patient’s survival by only taking the
factors as covariates, that were found to be significant in
univariate analysis.
Overall survival was calculated as the interval between
the date of the LT and either the date of death or the last
follow-up date of the patient. Recurrence-free survival
was calculated as the time from the date of LT until the
date of tumor recurrence and was censored at the time
of last following-up or death if at that time there was no
evidence of tumor recurrence.
All statistical analyses were conducted using the
SPSS version 17.0 (SPSS Inc. Chicago, IL). p <0.05 was
considered statistically significant.
Results
MiR-20a was down-regulated in primary HCC tissues
especially in those with tumor recurrence following LT
With the purpose of revealing the expression and signifi-
cance of miR-20a in HCC, we first detected the expression
of miR-20a in 100 cases of HCC and 10 normal liver tissueFigure 1 Decrease expression of miR-20a in HCC is associated with tu
miR-20a was measured in 100 FFPE HCC samples, 10 normal liver tissue, no
expression levels of miR-20a were normalized to U6 RNA expression for sub
down-regulated in HCC samples of patients with tumor recurrence after LT
who had died after LT than the patients who still survived. (D and E) Kapla
patients with HCC following LT according to the expression levels of miR-2by Taqman qPCR. The expression of miR-20a was signifi-
cantly down-regulated in HCC tissue compared with nor-
mal liver tissue (P = 0.001; Figure 1A) and the expression
levels of miR-20a were further down-regulated in HCCs
samples of patients with tumor recurrence after LT
(P = 0.020; Figure 1B). In accordance with the data between
recurrence and non-recurrence patients, the expression of
miR-20a was much lower in the patients who had died af-
ter LT than the patients who still survived (P < 0.001;
Figure 1C). At the same time, we also detected the expres-
sion level of miR-20a in normal liver cell line, LO2, and
three HCC cell lines, HepG2, SMMC-7721 and BEL-7402.
We found that the expression level of miR-20a in HCC
cell lines was lower than in LO2 cells, which was similar
with the results of clinical HCC samples (Figure 1A).
Decrease expression of miR-20a correlates with
aggressive tumor features
The relationships between miR-20a expression and clinico-
pathological features were analyzed based on the miR-20a
real-time PCR readings. As shown in Table 1, decrease
expression of miR-20a in HCC was associated significantly
with aggressive pathologic features, such as the largestmor recurrence and poor prognosis following LT. (A) Expression of
rmal liver cell line LO2 and 3 HCC cell lines by qRT-PCR, and the
sequent analyses. (B) The expression levels of miR-20a were further
. (C) The expression levels of miR-20a were much lower in the patients
n-Meier analyses of overall survival and recurrence-free survival in 100
0a.
Table 2 Univariate and multivariate Cox regression analyses of overall survival in 100 HCC patients following LT
Parameter Univariate analysis Multivariable analysis
HR 95% CI P-value HR 95% CI P-value
Age 0.875 0.912-1.172 0.169 - - -
Gender 1.034 0.561-1.907 0.915 - - -
HBV infection 0.342 0.261-0.745 0.230 - - -
Cirrhosis 0.833 0.495-1.438 0.467 - - -
Tumor size 1.319 1.012-1.894 0.021* 1.175 0.981-1.857 0.035*
Tumor stage (III) 2.938 1.359-5.493 0.018* 2. 354 0.846-2.943 0.851
Histologic grade (G3/G1-2) 3.342 1.837-6.421 0.009* 1.773 0.732-3.101 0.082
Milan criteria (out) 1.756 1.043-3.433 0.017* 1.365 0.935-2.778 0.347
AFP >400 (ng/ml) 2.027 1.386-3.543 0.023* 1.569 1.031-4.603 0.031*
Micro-vascular invasion 3.739 1.929-6.758 0.005* 2.671 1.756-5.545 0.009*
miR-20a (low) 4.483 2.769-9.572 0.009* 4.937 2.221-9.503 0.022*
Note: *statistically significant difference.
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micro-vascular invasion (P = 0.016).Decrease expression of miR-20a in HCC is associated with
tumor recurrence and poor prognosis
To further explore the clinical relevance of miR-20a,
Kaplan-Meier and univariate Cox proportional hazard
regression analyses were performed. Kaplan-Meier ana-
lysis showed decrease miR-20a expression correlated
with shorter overall survival (P < 0.001; Figure 1D) and
recurrence-free survival (P < 0.001; Figure 1E) of HCC
patients following LT. Similarly, univariate analysis
showed that miR-20a expression was associated with OS
(P = 0.009; Table 2) and RFS (P = 0.015; Table 3). The
other significant prognostic factors associated withTable 3 Univariate and multivariate Cox regression analyses of
Parameter Univariate analysis
HR 95% CI
Age 0.849 0.713-1.275
Gender 1.092 0.534-2.801
HBV infection 0.583 0.228-1.144
Cirrhosis 0.746 0.434-1.204
Tumor size 1.632 1.031-1.918
Tumor stage (III) 1.876 1.319-2.592
Histologic grade (G3/G1-2) 3.731 1.774-5.103
Milan criteria (out) 2.182 1.962-6.212
AFP >400 (ng/ml) 1.939 1.638-4.809
Micro-vascular invasion 4.017 3.137-7.583
miR-20a (low) 4.591 2.933-8.457
Note: *statistically significant difference.OS and RFS in univariate analyses were also shown
in Tables 2 and 3.MiR-20a independently predicts the survival of HCC
patient following LT
To get insight into the survival prediction potential of
miR-20a, we performed multivariate Cox proportional
hazard regression analyses to test whether miR-20a expres-
sion was an independent prognostic factor associated with
survival. Taking tumor size, tumor stage, histologic grade,
Milan criteria, pre-LT serum AFP level, micro-vascular
invasion and miR-20a as covariates, that were found to be
significant in univariate analysis, we found that decrease
miR-20a expression (HR = 4.937, P = 0.022; Table 2), tumor
size (HR = 1.175, P = 0.035; Table 2), pre-LT serum AFPrecurrence-free survival in 100 HCC patients following LT
Multivariable analysis
P-value HR 95% CI P-value
0.746 - - -
0.331 - - -
0.192 - - -
0.493 - - -
0.011* 1.253 1.123-1.792 0.014*
0.026* 1.348 0.935-1.813 0.365
0.024* 2.931 1.526-3.858 0.079
0.018* 1.935 1.332-3.563 0.156
0.012* 2.235 1.771-4.595 0.028*
0.009* 3.643 2.964-6.927 0.012*
0.015* 4.281 3.316-6.741 0.013*
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vascular invasion (HR = 2.671, P = 0.009; Table 2) were
significantly associated with OS and that the prognos-
tic value of miR-20a was independent the microvasculuar
invasion.
Similarly, decrease miR-20a expression (HR = 4.281,
P = 0.013; Table 3), tumor size (HR = 1.253, P = 0.014;
Table 3), pre-LT serum AFP level (HR = 2.235, P = 0.028;
Table 3) and micro-vascular invasion (HR = 3.643, P =
0.012; Table 3) significantly affected RFS of HCC patients
following LT.Figure 2 MiR-20a restoration in HCC cell lines inhibit proliferation an
miR-20a level in SMMC-7721 and HepG2 cells upon transfection with
response to miR-20 restoration. HepG2 or SMMC-7721 cells were seeded into
control oligonucleotide. Cell proliferation assay was done after culturing for 7
miR-20a on cell cycle progression of HCC cell lines. SMMC-7721 and HepG2 c
performed by flow cytometry. Data are given as mean ± SD of three indepen
in the number of cells in G1, S, or G2/M between miR-20a precursor transfectEffects of miR-20a restoration on HCC cell proliferation
and cell cycles in vitro
Cell proliferation is a key determinant of tumor malig-
nancy. However, the association of miR-20a with HCC
cell proliferation is unknown. To investigate whether
miR-20a up-regulation plays an important role in HCC
cell proliferation, HepG2 and SMMC-7721 cells were
transfected with miR-20a precursor and the effects of
miR-20 restoration were detected by Taqman qPCR
prior to the proliferation assay (Figure 2A and B). In cell
proliferation assay, the proliferation rate was suppressedd block cell cycle progression in vitro (A) and (B) Validation of
miR-20a precursor. (C) Proliferation assay of HCC cell lines in
96-well plates and incubated in the presence of miR-20a precursor or
2 h. The experiment was done in triplicate. (D) and (E) Influence of
ells were transfected with miR-20a precursor. Cell cycle analysis was
dent experiments. Asterisks indicate statistical significance of differences
ed and control oligo transfected cells (P < 0.05; Student’s t test).
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miR-20a precursor, and the inhibitory efficiencies were
41.3% and 39.0%, respectively (Figure 2C).
Cell cycle analysis was performed to determine whether
the effect of miR-20a on cell proliferation of HepG2 and
SMMC-7721 HCC cell lines was due to cell cycle arrest.
The result showed that when comparing to the control
oligonucleotide, the percentages of cells at G1 phase were
increased in both HCC cell lines (for HepG2, from 58.3%
to 80.0%, P = 0.003; for SMMC-7721, from 49.3% to
69.1%, P = 0.009), while the percentages of cells at S phase
were decreased in HepG2 (from 29.3% to12.7%, P = 0.003)
and SMMC-7721 (from 37.3% to 24.3%, P = 0.011)
(Figure 2D and E). All of these data demonstrated that
overexpression of miR-20a could induce the HCC cell
cycle G1 arrest and block cell cycle progression. Disap-
pointingly, the percentage of cells at G2/M phase was of
no statistic significance in HepG2 or SMMC-7721 cells
transfected with miR-20a when compared with the control
group, although the absolute value was decreased to a
certain extent (Figure 2D and E).
MiR-20a restoration induces HCC cells to apoptosis
To better understand the effect of proliferation inhib-
ition of miR-20a on HCC cells, we further investigatedFigure 3 MiR-20a restoration in HCC cell lines induces apoptosis a SM
were stained with FITC and PI. 20,000 cells were analyzed by flow cytom
(annexin V + and PI-) in the total cell population. Each type of cell was assa
presented as mean ± SD. Asterisks indicate statistical significance of differen
transfected and control oligonucleotide transfected cells (P < 0.05; Student’whether miR-20a could induce apoptosis of HCC cells.
Flow cytometry analysis showed that much more apop-
totic cells were observed in the miR-20a restoration
group compared with the control group (Figure 3). Sig-
nificant differences were observed both in SMMC-7721
(P < 0.001) and HepG2 (P = 0.005) HCC cells. The
apoptosis rates increased from 10.1% to 24.1% for
SMMC-7721 cells and from 12.9% to 23.1% for HepG2
cells after transfeted by miR-20 precursor.
MiR-20a directly regulates Mcl-1 expresion
The preceding findings indicated that miR-20a acted as
a proliferation suppressor in HCC. Therefore, we then
aimed to investigate the potential gene targets of
miR-20a that contributed to its antiproferation func-
tions. Potential target genes of miR-20a were first
predicted using online databases (TargetScan, PicTar,
and miRanda). Among them, Mcl-1 was chosen for
further experimental validation, not only because it was
identified as a target of miR-20a by all these three data-
bases, but also due to its frequent overexpression in tumor
tissues and well-known importance in the regulation of
cell-cycle progression [18] and anti-apoptotic activity [19].
Dual-luciferase reporter analysis showed that coexpression
of miR-20a significantly inhibited the activity of fireflyMC-7721 and HepG2 cells transfected with miR-20a precursor
etry. The LR quadrant represents the percentage of apoptotic cells
yed in triplicate. All data were processed by Student’s t test and
ces in the apoptosis rate of cells between miR-20a precursor
s t test).
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Mcl-1 (Figure 4A and B), indicating that miR-20a may
suppress gene expression throuth its binding site at
30UTR of Mcl-1. Moreover, introduction of miR-20a
diminished the expression of cellular Mcl-1 protein
expression in HepG2 and SMMC-7721 cells (Figure 4C).
Consistently, HCC tissues with low miR-20a showed
much higher Mcl-1 expression, compared with those
with high miR-20a expression by IHC detection (Figure
4D). These findings indicated that miR-20a might nega-
tively regulate the expression of Mcl-1 by directly
targeting its 30UTR.
Discussion
Recently, attentions have focused on the role of microRNA
regulation in essential mechanisms for cancer progression
and metastasis, including proliferation, invasion, migration,
angiogenesis and apoptosis. In human cancers, previous
studies have also shown that dysregulation of certain
microRNAs are associated with clinical outcomes ofFigure 4 MiR-20a directly regulates Mcl-1 expression. (A) Wild-type an
MicroRNA luciferase reporter assay. Wild type and mutant miR-20a target sequ
miR-20a precusor or control oligo into HEK293T cells. The firefly luciferase acti
MiR-20a significantly suppressed the luciferase activity of wild-type Mcl-1 30UT
Mcl-1 in HepG2 and SMMC-7721 HCC cells without transfection or cells transf
Mcl-1 and miR-20a expression in the same HCC tissue by IHC. Brown signal inpancreatic cancer [20], breast cancer [21], lung adenocar-
cinoma [22], gastric cancer [23], and HCC [24]. A few
reports even demonstrated that the expression profiling of
microRNAs may be a more accurate method of classifying
cancer subtype than using the expression profiles of
protein-coding genes [6,25].
In the present study, we confirmed that the expression
level of miR-20a was decreased in HCC tissues and three
HCC cell lines. Loss expression of miR-20a was associ-
ated with poor survival and tumor recurrence in HCC
patients who underwent LT. MiR-20a restoration could
suppress cell proliferation by inhibiting cell cycle pro-
gression and inducing apoptosis in vitro. Moreover, we
identified Mcl-1, which is an antiapoptotic member of
Bcl-2 family, as a direct and functional target of miR-20a.
To our best knowledge, this is the first study showing that
miR-20a regulates cellular proliferation in HCC cell and
correlates miR-20a to prognosis of HCC.
Although the expression of miR-20a is often down-
regulated in HCC, it is significantly up-regulated in lungd mutant of putative miR-20a target sequences of Mcl-1 30UTR. (B)
ences were fused with luciferase reporter and cotransfected with
vity of each sample was normalized to the Renilla luciferase activity.
R (p = 0.027). (C) Effects of miR-20a overexpression on the level of cellular
ected with NC or miR-20a were analyzed by western blot. (D) Analysis of
IHC was considered as positive staining for Mcl-1. Scale bar = 200 μm.
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discrepancy is likely due to the target genes of miR-20a
are different in different cancer cells and suggests that
altered expression of this microRNA may have diverse
effects in different tumor cells, either as an oncogene or
a tumor suppressor.
Mcl-1 is an antiapoptotic member of Bcl-2 family and
increased Mcl-1 protein level is commonly observed in
various types of cancers, including HCC [27]. Depletion of
Mcl-1 has been well proven to sensitize human HCC
cancer cells to apoptosis [28]. Furthermore, overexpression
of Mcl-1 is correlated with shorter survival of cancer pa-
tients [29]. All of these previous studies are consistent with
our findings that decrease expression of miR-20a promotes
HCC cell proliferation by targeting Mcl-1 which sensitizes
HCC cells to apoptosis. According to many other published
articles, Stat3, E2F family, cyclin-dependent kinase inhibitor
CDKN1a/p21 and transforming growth factor-beta recep-
tor 2 (TGFBR2) have also been identified as targets of miR-
20a. In addition, miR-20a also targets transforming growth
factor-beta receptor 2 (TGFBR2), which is a key mediator
of TGF-β signaling and strongly implicated in human
carcinogenesis [6]. Our identification of Mcl-1 as a target of
miR-20a provides new insights into the mechanisms
underlying HCC proliferation and resistance to apoptosis.Conclusions
We have shown that miR-20a was decreased in HCC tis-
sues and the expression level of miR-20a is a significant
prognostic factor for HCC patients. MiR-20a restoration
inhibited HCC cell proliferation and induced apoptosis
by directly targeting Mcl-1 30UTR. Our data not only
supply novel insights regarding miR-20a function and
the potential mechanisms of HCC cell proliferation, but
also suggest miR-20a may serve as a potential thera-
peutic target and biomarker for survival of HCC patients
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